Latest Sanofi Press Releases and News | Sanofi
Oct 21, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi US News
Sep 27, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To …
3 days ago · Sanofi and Regeneron are also studying dupilumab in a broad range of diseases driven in part by type-2 inflammation or other allergic processes in phase 3 studies. For More Such Health News, visit ...
Sanofi loses $21 bln in market value after dropping 2025 ...
Oct 27 (Reuters) - Sanofi (SASY.PA) stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its...
Press Room - Sanofi US News
Oct 16, 2024 · FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals. Read more.
Media, press releases, news and media resources - Sanofi
Oct 24, 2024 · Stay informed with Sanofi's latest news, press releases, and media resources. Explore updates from a global healthcare leader.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
Jun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
Dec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Sanofi US Media Room - Home
Oct 24, 2024 · Welcome to the Sanofi US Media Room. Our Media Room is designed to provide reporters with company and product news, as well as key facts, figures and background information. To help you keep up with the latest news, we offer email alerts and RSS feeds.
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
5 days ago · Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight PR Newswire Tue, Nov 12, 2024, 5:31 PM 10 ...
- Some results have been removed